Results of Operations and Financial Condition. On August 5, 2026, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended June 30, 2026 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are “forward-looking sta…

Results of Operations and Financial Condition. On May 6, 2026, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended March 31, 2026 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are “forward-looking state…

Director — Charles C. Duncan, Ph.D.: Dr. Charles C. Duncan was appointed as a new director of the company.

Senior Vice President, General Counsel and Secretary — Timothy Williams: Timothy Williams resigned to pursue other endeavors.

The filing details compensation arrangements and equity awards for the named executive officers, which is not a management change.

Results of Operations and Financial Condition. On February 11, 2026, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2025 (the “Earnings Call”). The full text of the press release, which includes information regarding Vanda’s use of Non-GAAP financial measures, is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporat…

Other Events. As previously disclosed, on October 1, 2025, Vanda Pharmaceuticals Inc. (“Vanda”) announced that it had reached a collaborative framework with the U.S. Food and Drug Administration (the “FDA”) pursuant to which, among other things, the FDA had agreed to conduct an expedited re-review of Vanda’s supplemental New Drug Application (the “sNDA”) for HETLIOZ ® for the treatment of jet lag disorder by January 7, 2026. On January 7, 2026, Vanda received a letter from the FDA stating tha…

Results of Operations and Financial Condition. On October 29, 2025, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended September 30, 2025 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are “forward-look…

Other Events. On October 1, 2025, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release announcing that it had reached a collaborative framework with the U.S. Food and Drug Administration for the resolution of certain disputes regarding Vanda’s drugs, HETLIOZ ® (tasimelteon) and tradipitant. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Results of Operations and Financial Condition. On July 31, 2025, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended June 30, 2025 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are “forward-looking stat…

Results of Operations and Financial Condition. On May 7, 2025, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended March 31, 2025 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are “forward-looking state…

The filing details compensation arrangements and equity awards for named executive officers, not a management change.

Results of Operations and Financial Condition. On February 13, 2025, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2024 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are…

Results of Operations and Financial Condition. On November 6, 2024, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended September 30, 2024 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are “forward-look…

Material Modification to Rights of Security Holders. The information included in

Entry into a Material Definitive Agreement. On August 7, 2024, Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”), entered into Amendment No. 2 (the “Amendment”) to that certain Rights Agreement, dated as of April 17, 2024, as amended by that certain Amendment No. 1 to the Rights Agreement, dated as of May 3, 2024 (“Amendment No. 1”), in each case by and between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New Yo…

Results of Operations and Financial Condition. On July 31, 2024, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended June 30, 2024 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are “forward-looking stat…

Results of Operations and Financial Condition. On May 8, 2024, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended March 31, 2024 (the “Earnings Call”). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are “forward-looking state…

Material Modification to Rights of Security Holders. The information included in

Entry into a Material Definitive Agreement. On May 3, 2024, Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”), entered into Amendment No. 1 (the “Amendment”) to that certain Rights Agreement, dated as of April 17, 2024 (the “Rights Agreement”), by and between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent. The Amendment amended the definition of “Exempt Person” to add BlackRock, Inc. and…

Material Modification to Rights of Security Holders. The information included in

Entry into a Material Definitive Agreement. On April 17, 2024, the Board of Directors (the “Board”) of Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”), authorized and declared a dividend distribution of one right (each, a “Right”) for each outstanding share of common stock, par value $0.001 per share (the “Common Stock”), of the Company to stockholders of record as of the close of business on April 29, 2024 (the “Record Date”). Each Right entitles the registered holder to p…

Other Events. On April 17, 2024, the Company issued a press release announcing the adoption of the Rights Agreement and the declaration of the dividend of Rights. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. Additionally, on April 17, 2024, the Company issued a press release announcing that its Board, in consultation with its independent financial and legal advisors, and consistent with its fiduciary duties, rejected unsolicited acquisition pro…

Other Events. On March 6, 2024, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release announcing that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding Vanda’s supplemental New Drug Application for HETLIOZ ® in the treatment of insomnia. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The filing details compensation arrangements and equity awards for named executive officers.